Gene therapy for the treatment of cancer

被引:16
作者
Buchsbaum, DJ
Curiel, DT
机构
[1] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Div Human Gene Therapy, Birmingham, AL 35294 USA
关键词
cancer gene therapy; viral vectors; nonviral vectors; mutation compensation; genetic immunopotentiation; molecular chemotherapy; inhibition of angiogenesis; replicative vector oncolysis; chemosensitization; and radiosensitization;
D O I
10.1089/108497801753131354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The delineation of the molecular basis of neoplasia provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches have been developed for the treatment of cancer: mutation compensation, genetic immunopotentiation, molecular chemotherapy, inhibition of angiogenesis, replicative vector oncolysis, and chemosensitization or radiosensitization. Clinical trials have been initiated to evaluate safety, toxicity, and efficacy of each of these approaches, based on promising preclinical results. Various limitations that have been identified include lack of in vivo selective tumor delivery of vectors, minimal expression of therapeutic genes, immune response against vectors, and normal tissue toxicity. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified, combined with advances in vector design, that gene therapy will play an increasing role in clinical cancer treatment.
引用
收藏
页码:275 / 288
页数:14
相关论文
共 86 条
[51]   Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [J].
Markert, JM ;
Medlock, MD ;
Rabkin, SD ;
Gillespie, GY ;
Todo, T ;
Hunter, WD ;
Palmer, CA ;
Feigenbaum, F ;
Tornatore, C ;
Tufaro, F ;
Martuza, RL .
GENE THERAPY, 2000, 7 (10) :867-874
[52]  
Maxwell IH, 1999, TUMOR TARGET, V4, P189
[53]  
McIvor R S, 1999, Pediatr Transplant, V3 Suppl 1, P116
[54]  
Nielsen LL, 1998, CANCER GENE THER, V5, P52
[55]   Effective treatment of experimental glioblastoma by HSV vector-mediated TNFα and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration [J].
Niranjan, A ;
Moriuchi, S ;
Lunsford, LD ;
Kondziolka, D ;
Flickinger, JC ;
Fellows, W ;
Rajendiran, S ;
Tamura, M ;
Cohen, JB ;
Glorioso, JC .
MOLECULAR THERAPY, 2000, 2 (02) :114-120
[56]   Genetic prodrug activation therapy for breast cancer:: A phase I clinical trial of erbB-2-directed suicide gene expression [J].
Pandha, HS ;
Martin, LA ;
Rigg, A ;
Hurst, HC ;
Stamp, GWH ;
Sikora, K ;
Lemoine, NR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2180-2189
[57]  
Pederson LC, 1997, CANCER RES, V57, P4325
[58]  
Piché A, 1998, CANCER RES, V58, P2134
[59]   Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector [J].
Ramesh, R ;
Saeki, T ;
Templeton, NS ;
Ji, L ;
Stephens, LC ;
Ito, I ;
Wilson, DR ;
Wu, Z ;
Branch, CD ;
Minna, JD ;
Roth, JA .
MOLECULAR THERAPY, 2001, 3 (03) :337-350
[60]  
Rancourt C, 1998, CLIN CANCER RES, V4, P2455